piperacillin--tazobactam-drug-combination and Flavobacteriaceae-Infections

A 7-month-old male infant presented with history of fever for 2 weeks, multiple ecchymotic patches over face, trunk and lower limbs, and one episode of seizure. The infant had shock, respiratory failure, severe anaemia, thrombocytopenia and temporoparietal haematoma on CT scan of the head. He was managed with supportive care and broad-spectrum empiric antibiotics. Two consecutive blood cultures grew

Topics: Anti-Bacterial Agents; Flavobacteriaceae; Flavobacteriaceae Infections; Humans; Infant; Male; Piperacillin, Tazobactam Drug Combination

Elizabethkingia meningoseptica is a multi-drug-resistant organism that is associated with high mortality and morbidity in newborn and immunocompromised patients. This study aimed to identify the best antimicrobial therapy for treating this infection.. A retrospective descriptive study was conducted from 2010 to 2017 in a tertiary paediatric hospital in Singapore. Paediatric patients aged 0 to 18 years old with a positive culture for E. meningoseptica from any sterile site were identified from the hospital laboratory database. The data collected included clinical characteristics, antimicrobial susceptibility and treatment, and clinical outcomes.. Thirteen cases were identified in this study. Combination therapy with piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluoroquinolone resulted in a cure rate of 81.8  %. The mortality rate was 15.4  % and neurological morbidity in patients with bacteraemia and meningitis remained high (75 %).. Treatment with combination therapy of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluroquinolone was effective in this study, with low mortality rates being observed.

Topics: Anti-Bacterial Agents; Child; Child, Preschool; Female; Flavobacteriaceae; Flavobacteriaceae Infections; Fluoroquinolones; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Singapore; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

Elizabethkingia meningoseptica is a non-fermentative Gram-negative bacillus that has emerged as an important pathogen in nosocomial infections and is usually associated with high mortality. E. meningoseptica is inherently resistant to many broad-spectrum antibiotics, and appropriate antibiotic selection is crucial for survival. Data about the therapeutic efficacy of fluoroquinolone in E. meningoseptica bacteraemia are limited. We retrospectively enrolled patients with E. meningoseptica bacteraemia who were treated with a single antimicrobial agent with in vitro activity against E. meningoseptica for at least 48 hours in a Taiwanese medical centre between January 2011 and June 2016. We compared the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment. A logistic regression and a propensity score-adjusted model were used to evaluate the risk factors for 14-day mortality. A total of 66 patients were identified, 24 who received fluoroquinolone treatment (ciprofloxacin, n = 9; levofloxacin, n = 15) and 42 who received non-fluoroquinolone treatment (piperacillin/tazobactam, n = 26; trimethoprim/sulfamethoxazole, n = 15; minocycline, n = 1). The fluoroquinolone group had significantly lower 14-day mortality than the non-fluoroquinolone group (8.3% vs. 33.3%, P = 0.023). The APACHE II score was significantly higher in the non-fluoroquinolone group than in the fluoroquinolone group. In a propensity-adjusted analysis, fluoroquinolone use was an independent factor associated with 14-day survival. After stratification using the APACHE II score, treatment with fluoroquinolone was associated with 14-day survival, but did not reach statistical significance in both groups with greater and lesser severity. Therefore, fluoroquinolone is a suitable antimicrobial agent for treating E. meningoseptica bacteraemia.

Topics: Aged; Anti-Bacterial Agents; Bacteremia; Chryseobacterium; Cross Infection; Female; Flavobacteriaceae Infections; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Taiwan; Trimethoprim, Sulfamethoxazole Drug Combination

Elizabethkingia meningoseptica is a multi-drug resistant organism that can cause meningitis in premature neonates. We report a case of Elizabethkingia meningoseptica meningitis that was detected early in an extremely premature low birth weight infant. He was successfully treated with a combination of ciprofloxacin and piperacillin-tazobactam. The spread of infection was controlled with no other reported cases.

Topics: Anti-Bacterial Agents; Ciprofloxacin; Flavobacteriaceae; Flavobacteriaceae Infections; Humans; Infant, Newborn; Male; Meningitis, Bacterial; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Saudi Arabia; Treatment Outcome

A case of non-catheter-related bacteremia caused by Chryseobacterium indologenes in a nonneutropenic man with a solid tumor is described. The patient was successfully treated with piperacillin-tazobactam.

Topics: Anti-Bacterial Agents; Bacteremia; Carcinoma, Squamous Cell; Chryseobacterium; Drug Therapy, Combination; Flavobacteriaceae Infections; Humans; Lymphatic Metastasis; Male; Middle Aged; Nose Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination